# AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

> **NCT04468659** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eisai Inc.** · enrollment: 1400 (estimated)

## Conditions studied

- Preclinical Alzheimer's Disease
- Early Preclinical Alzheimer's Disease

## Interventions

- **DRUG:** Lecanemab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04468659
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-14
- **Primary completion:** 2028-12-21
- **Final completion:** 2031-01-16
- **Target enrollment:** 1400 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04468659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04468659, "AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT04468659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*